Small molecule and ADC standouts – a guest post
How to stand out from the early-stage competition
Challenges and opportunities go hand in hand with early drug development
Is casdatifan the best in class HIF2α inhibitor?
Which Thunderbirds are Go in this niche?!
More gems from the TARGETS23 poster halls
Searching for well tolerated combinations in the KRAS niche
From small acorns, so oak trees grow
What to watch out for in DDR, epigenetic therapies, and other hot topics
From epigenetics to SHP2, a look at various upcoming presentations this month
A look at some hot topics from the TARGETS/TRIPLE meeting in Boston
What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…
Reprogramming T cell phenotype is becoming a hot topic in solid tumours and here's why...
Beyond KRAS - targeting another of the four horsemen of the apocalypse
A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting
Where next in the ever expanding KRAS runners and riders?
Will Relay's FGFR2 live up to expectations?
It’s time to look at progress on the ADC front, something we sporadically cover where there are new…
What can we learn from KRASi combinations? Do any stand out?
We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat
The devil is in the finer details...
It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…
The trials and tribulations of targeted agents in developmental therapeutics
Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus
An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche
Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.
How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.
KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib
Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?
What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?
On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...
How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...
Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.
A look at loss of heterozygosity and what it means for new lung cancer therapies
A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly
Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.
Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia
A look at some of the important data coming out of Day 2 of #Targets17 in Philadelphia
Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia
Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
A draft manifesto for IO in cancer research and what we need to learn
A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma
Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich
Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?
Highlights from the Charles River Immunotherapy Symposium in Munich, 2016
AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.
Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...
Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed
Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona
Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona
What new clinical approaches are being investigated to overcome resistance in melanoma?
Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.
The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...
The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.
An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).
An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!
Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.
Cerulean are developing a novel nanopharmaceutical that targets HIF1-alpha and is synergistic with anti-angiogenic drugs for RCC and Ovarian cancers.
At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.
Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston
